Trials / Not Yet Recruiting
Not Yet RecruitingNCT07349615
A Study of SHR-1918 In Participants With Hypertriglyceridemia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypertriglyceridemia
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1918/ SHR-1918 placebo | SHR-1918/ SHR-1918 placebo Dose 1 |
| DRUG | SHR-1918/ SHR-1918 placebo | SHR-1918/ SHR-1918 placebo Dose 2 |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2027-11-01
- Completion
- 2027-11-01
- First posted
- 2026-01-20
- Last updated
- 2026-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07349615. Inclusion in this directory is not an endorsement.